Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Filetti

Showing results (51-60 of 81) with videos related to

Pageof 9
Sort By:
Cancers|January 30, 2019
A Simplified Genomic Profiling Approach Predicts Outcome in Metastatic Colorectal CancerCarlo Capalbo, Francesca Belardinilli, Domenico Raimondo, et al.
Journal for Immunotherapy of Cancer|August 8, 2020
Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genesMarco Mazzotta, Marco Filetti, Mario Occhipinti, et al.
European Journal of Cancer (Oxford, England : 1990)|December 8, 2024
An international survey on the knowledge, attitudes and clinical patterns of use of medical cannabis for cancer care: The TASMAN studyDario Trapani, Sara J Nidhamalddin, Sara Gandini, et al.
Clinical Lung Cancer|March 20, 2019
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC PatientsAlessio Cortellini, Rita Chiari, Biagio Ricciuti, et al.
European Journal of Cancer (Oxford, England : 1990)|February 29, 2020
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse eventsAlessio Cortellini, Melissa Bersanelli, Daniele Santini, et al.
Cancer Letters|June 5, 2024
Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort studyKylie Fletcher, Alessio Cortellini, Teja Ganta, et al.
Journal for Immunotherapy of Cancer|November 6, 2020
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practiceAlessio Cortellini, Marco Tucci, Vincenzo Adamo, et al.
JAMA Oncology|November 4, 2021
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort StudyCaroline A Nebhan, Alessio Cortellini, Weijie Ma, et al.
Journal for Immunotherapy of Cancer|May 21, 2021
INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2)Melissa Bersanelli, Diana Giannarelli, Ugo De Giorgi, et al.
The Oncologist|February 24, 2019
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse StudyAlessio Cortellini, Sebastiano Buti, Daniele Santini, et al.
Pageof 9

Showing results (51-60 of 81) with videos related to

Sort By:
Pageof 9
Cancers|January 30, 2019
A Simplified Genomic Profiling Approach Predicts Outcome in Metastatic Colorectal CancerCarlo Capalbo, Francesca Belardinilli, Domenico Raimondo, et al.
Journal for Immunotherapy of Cancer|August 8, 2020
Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genesMarco Mazzotta, Marco Filetti, Mario Occhipinti, et al.
European Journal of Cancer (Oxford, England : 1990)|December 8, 2024
An international survey on the knowledge, attitudes and clinical patterns of use of medical cannabis for cancer care: The TASMAN studyDario Trapani, Sara J Nidhamalddin, Sara Gandini, et al.
Clinical Lung Cancer|March 20, 2019
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC PatientsAlessio Cortellini, Rita Chiari, Biagio Ricciuti, et al.
European Journal of Cancer (Oxford, England : 1990)|February 29, 2020
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse eventsAlessio Cortellini, Melissa Bersanelli, Daniele Santini, et al.
Cancer Letters|June 5, 2024
Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort studyKylie Fletcher, Alessio Cortellini, Teja Ganta, et al.
Journal for Immunotherapy of Cancer|November 6, 2020
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practiceAlessio Cortellini, Marco Tucci, Vincenzo Adamo, et al.
JAMA Oncology|November 4, 2021
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort StudyCaroline A Nebhan, Alessio Cortellini, Weijie Ma, et al.
Journal for Immunotherapy of Cancer|May 21, 2021
INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2)Melissa Bersanelli, Diana Giannarelli, Ugo De Giorgi, et al.
The Oncologist|February 24, 2019
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse StudyAlessio Cortellini, Sebastiano Buti, Daniele Santini, et al.
Pageof 9